Screener
Intellia Therapeutics NTLA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 82,595 | 97,035 | 163,332 | 205,462 |
| General and administrative | 37,824 | 27,206 | 72,667 | 56,213 |
| Total operating expenses | 120,419 | 124,241 | 235,999 | 261,675 |
| Operating loss | (112,760) | (109,996) | (213,292) | (230,803) |
| Other income, net: | ||||
| Interest income | 5,797 | 7,402 | 11,002 | 16,005 |
| Change in fair value of investments, net | 329 | 1,339 | (575) | (786) |
| Total other income, net | 6,126 | 8,741 | 10,427 | 15,219 |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's operating income?
- Intellia Therapeutics (NTLA) reported operating income of -$112.76M in Q2 2026.
- How has Intellia Therapeutics's operating income changed year-over-year?
- Intellia Therapeutics's operating income decreased by 2.5% year-over-year, from -$110M to -$112.76M.
- What is the long-term trend for Intellia Therapeutics's operating income?
- Over 4 years (2021 to 2025), Intellia Therapeutics's operating income has grown at a 13.3% compound annual growth rate (CAGR), from -$267.85M to -$440.99M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Intellia Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude